文献速递白血病MDS 与骨髓增殖性肿瘤

维奈克拉联合去甲基化药物治疗急性髓系白血病中的侵袭性真菌感染

Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents.
PubMed 文献 · Blood Adv · 2019-01-01

该回顾性研究纳入119例接受维奈克拉联合去甲基化药物(VEN-HMA)治疗的急性髓系白血病(AML)患者,分析侵袭性真菌感染(IFI)的发生及抗真菌预防实践。结果显示15例(12.6%)发生可能或确诊IFI,中位起病时间为开始治疗后72天;未缓解者及复发/难治患者的IFI风险更高,而预防药物类型、年龄等因素未见影响。

要点

  • VEN-HMA治疗期间IFI总体风险较低,但未缓解者和复发/难治患者风险显著升高。
  • IFI中位起病时间为治疗开始后72天,需长期监测。
  • 抗真菌预防药物类型、年龄、HMA方案等未影响IFI发生。

核心结论

  • VEN-HMA治疗期间IFI总体风险低,但未缓解者和复发/难治患者风险更高。

研究设计与样本

  • 回顾性队列研究,纳入119例接受VEN-HMA治疗的AML患者。

主要发现

  • 15例(12.6%)发生可能或确诊IFI,中位起病时间为开始治疗后72天(范围35-281天)。
  • 抗真菌预防药物类型、患者年龄、HMA方案、既往异基因移植史及初始中性粒细胞减少持续时间未影响IFI发生。

关键数值与推荐

  • 计划抗真菌预防:38%患者使用米卡芬净,41%使用唑类,21%未预防。

临床怎么用

  • 对VEN-HMA治疗的未缓解及复发/难治AML患者应重新评估抗真菌预防策略以降低IFI风险。

局限性

  • 回顾性研究设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The combination of venetoclax with hypomethylating agents (VEN-HMAs) showed promising activity in newly diagnosed and relapsed/refractory (r/r) acute myeloid leukemia (AML). Treatment with VEN-HMAs results in prolonged cytopenia, thereby exposing patients to invasive fungal infections (IFIs). Here, we retrospectively studied a cohort of 119 AML patients treated with VEN-HMAs and analyzed the occurrence of IFIs, as well as our practice of antifungal prophylaxis, with the aim to identify the nature and risk factors for IFIs and their association with the type of antifungal prophylaxis used. The intended antifungal prophylaxis was micafungin in 38% of patients, azoles in 41% of patients, and none in 21% of patients. Older age was associated with no antifungal prophylaxis or micafungin use and lesser use of azoles (P = .043). We recorded 15 (12.6%) patients who developed probable or proven IFIs, with a median onset of 72 days (range, 35-281) after starting therapy. IFIs were more common among nonresponders compared with responders to VEN-HMA therapy (22% vs 6%, P = .0132) and in r/r compared with newly diagnosed AML (19% vs 5%, P = .0498); however, the antifungal prophylaxis used, patient age, hypomethylating agent schedule, history of prior allogeneic transplant, and initial neutropenia duration did not influence the development of IFIs during therapy. We conclude that the overall risk of IFIs during VEN-HMA therapy is low. The risk of IFIs is higher in nonresponders and in those who were treated in the r/r setting; these patients need reevaluation of their antifungal prophylaxis to minimize the risk of IFIs during therapy.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Aldoss I, Dadwal S, Zhang J, et al. Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents. Blood Adv. 2019. PMID: 31816059. doi:10.1182/bloodadvances.2019000930

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。